Executive Clinical Snapshot
Prof. Ping Fu, MD, PhD, FASN, is the Director of the Department of Nephrology and Director of the Kidney Research Institute at West China Hospital, Sichuan University. A Fellow of the American Society of Nephrology (FASN) and President of the Chinese Association of Blood Purification Management (CABPM), Prof. Fu is widely recognized as one of the world's leading authorities in critical care nephrology and blood purification. He has spearheaded transformative advances in Continuous Renal Replacement Therapy (CRRT), regional citrate anticoagulation (RCA) protocols, and multi-modal hybrid blood purification (including double-filtration plasmapheresis and targeted cytokine adsorption) for acute kidney injury (AKI), multiorgan failure, and medically refractory autoimmune glomerulonephritis.
Academic Leadership & National Standing
- Director, Department of Nephrology & Kidney Research Institute, West China Hospital, Sichuan University.
- Fellow of the American Society of Nephrology (FASN).
- President, Chinese Association of Blood Purification Management (CABPM).
- Vice Chairman, Chinese Society of Nephrology (CSN), Chinese Medical Association.
- Chairman, Sichuan Provincial Nephrology Quality Control Center.
- Lead Investigator & National Principal Investigator for major multi-center clinical trials on citrate anticoagulation in high-bleeding-risk CRRT, novel mineralocorticoid receptor antagonists in diabetic nephropathy, and complement inhibitors in atypical hemolytic uremic syndrome (aHUS).
Therapeutic Breakthroughs: The Precision Blood Purification Paradigm
Critically ill patients suffering from severe sepsis, multi-organ dysfunction syndrome (MODS), or fulminant autoimmune crises frequently experience acute kidney injury accompanied by severe coagulopathy. Conventional heparin anticoagulation in dialysis circuits poses catastrophic risks of fatal internal bleeding, while circuit clotting causes frequent interruptions and therapeutic failure. Prof. Fu solved these clinical bottlenecks through rigorous clinical translational engineering:
Key Nephrological Innovations Pioneered by Prof. Ping Fu:
- Standardized Regional Citrate Anticoagulation (RCA) Protocols: Developed and validated safe, algorithm-driven citrate anticoagulation protocols that prolong CRRT filter lifespan beyond 72 hours without inducing systemic anticoagulation, effectively eliminating bleeding complications in postsurgical and trauma patients.
- Hybrid Blood Purification (HBP) for Cytokine Storms: Engineered integrated treatment cascades coupling continuous veno-venous hemodiafiltration (CVVHDF) with selective macroporous resin hemoperfusion (e.g., HA380/HA330) and double filtration plasmapheresis (DFPP) to clear circulating endotoxins, inflammatory storm mediators, and pathogenic autoantibodies in severe sepsis and acute pancreatitis.
- Precision Glomerulonephritis Targeted Immunotherapy: Integrated high-resolution renal histopathology, single-cell RNA sequencing, and serum autoantibody profiling (e.g., anti-PLA2R, anti-THSD7A) to formulate personalized, steroid-sparing biologics regimens (rituximab, obinutuzumab, and belimumab) for resistant membranous nephropathy and lupus nephritis.
- Complex Vascular Access Salvage for Dialysis: Masters ultrasound-guided percutaneous transluminal angioplasty (PTA), central venous occlusion recanalization, and hybrid arteriovenous graft (AVG) placements for difficult, exhausted end-stage renal disease (ESRD) vascular access.
Comprehensive Nephrological Scope & Clinical Spectrum
- Critical Care Nephrology & Acute Kidney Injury: Severe septic shock-associated AKI, cardiorenal syndrome Type 1–4, and hepatorenal syndrome managed with tailored continuous renal replacement therapy.
- Refractory Autoimmune Glomerulopathies: Treatment-resistant lupus nephritis (ISN/RPS Class III/IV/V), ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis), and anti-GBM disease.
- Primary Glomerular Diseases: Refractory idiopathic membranous nephropathy, high-risk IgA nephropathy, focal segmental glomerulosclerosis (FSGS), and minimal change disease.
- Chronic Kidney Disease & Diabetic Nephropathy: Renal-protective multi-target pharmacotherapy (SGLT2 inhibitors, non-steroidal MRAs, GLP-1 RAs), cardiorenal metabolic risk mitigation, and dialysis delay strategies.
- Therapeutic Apheresis: Double filtration plasmapheresis (DFPP), plasma exchange (TPE), and immunoadsorption for ABO-incompatible kidney transplant desensitization and myasthenia gravis crises.
Benchmark Clinical Scenarios
Scenario A: Severe Septic Shock with Anuric AKI and Acute Coagulopathy
A 54-year-old male suffered septic shock, severe acute necrotizing pancreatitis, and anuric acute kidney injury with platelet counts dropping to 28 × 10⁹/L and active gastrointestinal bleeding. Traditional heparin dialysis was strictly contraindicated. Prof. Fu implemented a customized regional citrate anticoagulation CVVHDF regimen paired with coupled plasma filtration adsorption (CPFA). Over 96 hours of uninterrupted treatment, inflammatory markers (IL-6, TNF-alpha) dropped by over 80%, urine output gradually resumed, gastrointestinal hemorrhage ceased, and renal function completely recovered to baseline without requiring maintenance hemodialysis.
Scenario B: Multi-Drug Refractory Anti-PLA2R-Positive Membranous Nephropathy
A 41-year-old female with massive nephrotic syndrome (proteinuria 14.8 g/24h, serum albumin 16 g/L) failed standard cyclical cyclophosphamide and calcineurin inhibitor therapies, developing steroid-induced osteonecrosis. High-titer anti-PLA2R antibodies persisted at 480 RU/mL. Prof. Fu devised a personalized targeted regimen utilizing double filtration plasmapheresis (DFPP) to rapidly clear pathogenic IgG4 antibodies, followed by precision B-cell depletion with rituximab monitored by CD19/CD20 flow cytometry. Within six months, complete serological and clinical remission was achieved with complete resolution of proteinuria.
Scientific Impact & Clinical Publications
Prof. Ping Fu has published more than 200 high-impact papers in premier medical journals including Kidney International, Journal of the American Society of Nephrology (JASN), Critical Care, and American Journal of Kidney Diseases (AJKD). He has led the authoring of national expert consensus guidelines on CRRT citrate anticoagulation and blood purification center quality control, and is a frequent guest speaker at World Congress of Nephrology (WCN) and ASN Kidney Week.
International Patient Access via CMCS
Cross-border patients experiencing progressive renal deterioration, refractory proteinuria, complicated autoimmune renal disorders, or requiring advanced blood purification second opinions can coordinate directly with Prof. Ping Fu's clinical team at West China Hospital through China Medical Concierge – Shanghai (CMCS):
- Renal Histopathology & Laboratory Re-evaluation: Secondary expert microscopic review of kidney biopsy slides (light microscopy, immunofluorescence, and electron microscopy) and serological panels prior to travel.
- Virtual Pre-Travel Nephrology Consultation: Structured remote video conference to review renal functional trajectory, steroid-sparing immunosuppressive options, or blood purification alternatives.
- Priority Inpatient Admission & Specialized Nephrology Suites: Direct admission to West China Hospital's specialized inpatient nephrology units, ensuring rapid initiation of diagnostic or therapeutic protocols.
- Bilingual Medical Escort & Clinical Case Oversight: Full-time bilingual case managers overseeing medication administration, dialysis scheduling, laboratory updates, and renal dietetics.
- Long-Term Renal Follow-up & Cross-Border Continuity: Seamless transmission of treatment summaries, immunosuppressant monitoring schedules, and digital coordination with local nephrologists.
Connect with CMCS Medical Concierge
For confidential clinical inquiries, renal biopsy reviews, or to schedule a nephrology consultation with Prof. Ping Fu:
Email: contract@medicalsh.com
WhatsApp: Connect on WhatsApp
Official Website: www.medicalsh.com
0 comentarios